Its also for those who are overweight with a weight-related condition like high blood pressure or diabetes
For instance, ROS can induce the formation of carbonyl groups on proteins, altering their structure and antigenicity

These treatments should be offered to adults who meet all of the following: At least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease) BMI of 35 kg/m or above (or 32.5 kg/m or above for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) Access to a specialist weight management service that provides multidisciplinary support, including dietary advice, physical activity programmes, and behavioural interventions Treatment is typically time-limited to up to 2 years Previous unsuccessful attempts at weight loss through lifestyle measures alone Orlistat may be considered for adults with a BMI of 28 kg/m or above with associated risk factors (such as type 2 diabetes or cardiovascular disease), or 30 kg/m or above without additional risk factors

Occasional missed doses have minimal long-term impact on efficacy, though regular adherence produces the most consistent results